Hi Folks,
For emerging medical-device companies, FDA clearance is an important milestone.
But it isn't the finish line.
The more consequential phase begins when a company moves from product development and regulatory review into the marketplace—where physician adoption, patient demand, reimbursement, and execution begin determining whether the technology can become a meaningful commercial business.
That is where Modular Medical Inc. (Nasdaq: MODD) finds itself today.
The company received FDA 510(k) clearance in April 2026 for its next-generation Pivot™ tubeless insulin patch pump, followed by initial U.S. commercial availability beginning June 24.
Now, Modular Medical is preparing for the next stage of that rollout.
And for investors following the company, this may be the point where the story becomes considerably more interesting.
From FDA Clearance to Commercial Execution
Pivot™ is designed as a simplified insulin delivery system for adults who have historically remained on multiple daily injections rather than transitioning to pump therapy.
According to the company, the product is now commercially available in the United States, marking Modular Medical's transition from a development-stage medical-device company into a commercial-stage business.
But the larger rollout is just beginning.
On August 3, Modular Medical announced plans to initiate the first phase of its full commercial launch across five strategically selected U.S. markets beginning in October 2026:
Atlanta
Cincinnati/Lexington
Dallas
Houston
Philadelphia
Those markets were not selected arbitrarily.
Management analyzed insurance claims, prescription activity, and adoption patterns across more than 100 U.S. markets before determining where it believed Pivot™ was best positioned to gain early traction.
According to data cited by Modular Medical, the five initial markets collectively represent:
• 14% of the nation's highest-volume insulin pump prescribers
• 15% of all new insulin pump starts
• 21% of prescribers demonstrating historically high adoption of new brands among patients using multiple daily injections
The underlying data was sourced from PurpleLab medical and pharmacy claims covering the 24 months ended June 2025.
That gives Modular Medical a focused, data-driven starting point rather than attempting an expensive nationwide rollout from day one.
A Capital-Efficient Commercial Strategy
This is an important distinction.
For an emerging healthcare company, commercial expansion can consume capital quickly. Building a nationwide sales organization before establishing product-market fit can create significant financial pressure.
Modular Medical appears to be taking a more measured approach.
The initial five-market rollout is designed to establish a commercial foundation, generate real-world adoption data, and provide management with information that can guide subsequent geographic expansion.
The company has also partnered with Inizio, a global commercialization organization with experience in metabolic health and diabetes care.
Inizio is expected to provide commercial execution, provider engagement, and launch-support resources intended to accelerate physician awareness and patient adoption across the company's initial markets.
CEO Jeb Besser described the five-market launch as a critical first step in Modular Medical's commercialization strategy.
The logic behind that strategy is straightforward.
Millions of patients continue using multiple daily insulin injections even though pump technology has existed for years.
Modular Medical believes complexity, cost, inconvenience, and usability remain meaningful barriers preventing broader adoption.
Pivot™ was built specifically to address that population.
The $3 Billion "Almost-Pumper" Catalyst
This may be the most important part…
According to Modular Medical, approximately 4.8 million Americans require daily insulin, yet only about 20% currently use an insulin pump.
That leaves a substantial population continuing to manage diabetes through multiple daily injections.
The company refers to these patients as "almost-pumpers."
These are individuals who could potentially benefit from pump therapy but have avoided existing systems because they may be perceived as too expensive, complicated, burdensome, or difficult to incorporate into everyday life.
Modular Medical estimates this underserved segment represents approximately a $3 billion addressable market within the broader diabetes technology industry.
Pivot™ was developed specifically with this population in mind.
The product emphasizes simplicity, usability, and affordability while offering the convenience of a tubeless patch-pump design.
According to the company, Pivot™ is also the first FDA-cleared two-part tubeless insulin patch pump available in the United States.
That gives Modular Medical a differentiated product as it enters an established and sizable market.
Leadership With Deep Insulin-Pump Experience
There is another element of this story that shouldn't be overlooked.
Paul DiPerna, the founder of Modular Medical, previously founded Tandem Diabetes Care, one of the better-known companies in the insulin delivery industry.
Tandem generated approximately $1 billion in revenue in 2025, and DiPerna is credited with inventing and designing the company's widely recognized t® insulin pump.
Past success never guarantees future results.
But in medical technology—where product design, regulatory navigation, manufacturing, reimbursement, physician adoption, and commercialization all matter—relevant operating experience can be particularly valuable.
Modular Medical enters its commercial phase with leadership that has already participated in building a significant insulin-delivery business.
Seven Reasons MODD Deserves Close Attention
• FDA Clearance Is Behind It
Pivot™ received FDA 510(k) clearance in April 2026 and moved into U.S. commercial availability on June 24.
That means Modular Medical is no longer dependent solely on achieving regulatory clearance. The focus can now shift toward adoption and execution.
• Patients Are Already Using Pivot™
According to Modular Medical, its first patients are actively using the Pivot™ tubeless insulin patch pump in real-world settings.
That represents an important transition from regulatory approval to actual patient utilization.
• A Targeted Five-Market Launch Begins in October
Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia will form the initial phase of the company's broader commercialization strategy.
These markets were selected based on prescribing volume, new pump adoption, and physician willingness to adopt new products.
• Pivot™ Offers Product Differentiation
According to company disclosures, Modular Medical is one of only two companies currently offering a fully electronic tubeless insulin pump in the United States.
The company also describes Pivot™ as the first FDA-cleared two-part tubeless insulin patch pump available in the country.
• International Expansion Could Follow
Management is pursuing CE Mark approval for European markets, with a targeted regulatory timeline of Q4 2026 or Q1 2027.
Successful approval would give Modular Medical another potential avenue for geographic expansion.
• The Pipeline Extends Beyond Pivot™
The company has entered into a licensing and partnership agreement with Nudge BG to develop a closed-loop automated insulin delivery system.
Modular Medical is also conducting a proof-of-concept program evaluating its MODD1 platform for personalized GLP-1 metabolic therapy.
Those initiatives provide additional potential growth avenues beyond the company's initial insulin-pump commercialization effort.
• The Addressable Market Is Significant
Modular Medical is pursuing a population drawn from approximately 4.8 million Americans requiring daily insulin, many of whom remain outside pump therapy.
Management estimates the "almost-pumper" addressable market at roughly $3 billion, within an approximately $8 billion global insulin pump market.
What I’ll Be Watching Next
The investment case now becomes much more measurable.
FDA clearance has already been achieved.
Initial commercialization has begun.
The first patients are using the product.
And a focused five-market rollout is scheduled to begin in October.
From here, the questions become operational:
Can Modular Medical generate meaningful physician adoption?
Will patients respond to Pivot™'s simplified design?
Can the Inizio partnership accelerate awareness without requiring excessive capital?
And, most importantly, can early traction in these five markets support a broader national expansion?
Those are the metrics that will begin separating promise from execution.
The Bottom Line
Modular Medical has reached a point that relatively few emerging medical-device companies ever achieve.
It has moved beyond development.
It has secured FDA clearance.
It has begun placing its technology into patients' hands.
And it is preparing for a carefully targeted commercial expansion into five strategically chosen U.S. markets.
There is still considerable work ahead. Commercial adoption, reimbursement, physician acceptance, manufacturing execution, and disciplined capital allocation will ultimately determine whether Pivot™ becomes a meaningful competitor in the insulin-delivery market.
But the pieces are beginning to come together.
With an FDA-cleared product, a $3 billion addressable market, experienced industry leadership, an October commercial expansion, a European regulatory pathway, and additional technologies under development, Modular Medical has entered a stage where its progress deserves close attention.
For investors following emerging medical technology companies, MODD belongs on the watchlist.
I'll continue monitoring the company's commercial rollout and will keep you informed as the next milestones develop.
To your success,
Michael Reece
© 2026 FinancialDrivenResearch.com. All rights reserved. You are receiving this e-mail as part of your subscription to FinancialDrivenResearch.com. Nothing in this e-mail should be considered personalized financial advice. We are neither a registered investment adviser nor a broker/dealer. Readers are advised that this electronic publication is issued solely for information purposes only and should not be construed as an offer to sell or the solicitation of an offer to buy any security. FDR is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Pursuant to an agreement between FDR and STM LLC. FDR has been previously compensated fifteen thousand USD to publicly disseminate information about MODD via digital communications. We own zero shares of MODD.